What Is Spinal Muscular Atrophy? Explained

Spinal muscular atrophy is a genetic disease that attacks the motor neurons in the spinal cord, the nerve cells that carry movement signals from the brain to the muscles. As those neurons are lost, muscles weaken and shrink. It is a leading genetic cause of infant death, but it also affects children and adults, and the range of severity is wider than most people realize.

What Is Spinal Muscular Atrophy?

Spinal muscular atrophy, usually shortened to SMA, is an inherited condition caused by a flaw in a gene called SMN1. That gene holds the instructions for a protein every motor neuron needs to survive. When SMN1 does not work, motor neurons gradually die, and the muscles they control waste away.

What makes SMA unusual is that the disease is not one condition but a spectrum. Some babies are born with severe weakness and never sit without help. Others have mild leg weakness that first shows up in adulthood. Both can carry the same faulty gene. The difference often comes down to a second, nearly identical gene called SMN2.

SMA is not a muscle disease in the usual sense. The muscles themselves start out healthy. The problem is upstream, in the nerve cells that tell them to move. That distinction matters because it shapes how the disease behaves and how it is treated.

What Causes Spinal Muscular Atrophy?

SMA is caused by mutations in the SMN1 gene. In the most common form, both copies of the gene — one inherited from each parent — are missing or faulty. A person with only one faulty copy is a carrier and typically has no symptoms.

Here is the part that surprises many people. Humans have a backup gene called SMN2 that makes the same protein, but it does so inefficiently. Most of the protein it produces is shortened and breaks down quickly. Only a small fraction is full-length and functional.

People inherit different numbers of SMN2 copies. Someone with more copies tends to make more usable protein and often has a milder form of the disease. Someone with fewer copies tends to have a more severe form. This is why two siblings with the same SMN1 mutation can be affected very differently.

SMN2 copy number is a strong predictor, not a perfect one. It is one of the clearest examples in genetics of a “modifier gene” shaping how a disease plays out.

How Is Spinal Muscular Atrophy Inherited?

SMA follows an autosomal recessive pattern. That means a child must inherit a faulty SMN1 copy from each parent to be affected. Parents who each carry one faulty copy have a 1 in 4 chance, with each pregnancy, of having a child with SMA.

Carrier status is common. Roughly 1 in 40 to 1 in 60 people carry a faulty SMN1 copy, depending on the population. Most carriers have no family history and no idea they carry it, because carrying one faulty copy causes no symptoms.

Because inheritance is recessive, SMA can appear in a family with no prior cases. This is why some health authorities offer carrier screening, particularly for people planning a pregnancy or with a family history. Screening can identify couples at risk before a child is affected.

What Are the Types of Spinal Muscular Atrophy?

Clinicians group SMA into types based on the age symptoms begin and the highest level of motor function a person reaches. The boundaries between types are not sharp, and some people fall between categories.

• Type 0 is the most severe and appears before birth. It is rare.
• Type 1 begins in the first months of life. Babies have severe weakness, poor muscle tone, and trouble breathing and swallowing.
• Type 2 usually appears between 6 and 18 months. Children can sit without support but do not walk independently.
• Type 3 begins after 18 months, often in childhood or the teen years. People can walk at some point, though many lose that ability over time.
• Type 4 begins in adulthood, usually after age 30, and is the mildest form.

These categories were built before modern treatments existed and are used less rigidly now. Many clinicians describe a person’s function directly rather than relying only on a type label.

What Are the Symptoms of Spinal Muscular Atrophy?

The core symptom is muscle weakness that is worse near the center of the body and in the legs, while the eyes and the muscles of the face are usually spared. Sensation, thinking, and the senses are not affected. SMA does not damage the brain’s cognitive function.

In infants, early signs include a “floppy” feel, weak cry, poor head control, and difficulty feeding or breathing. In older children and adults, the first signs are often trouble climbing stairs, a tendency to trip, or difficulty rising from a chair.

Weakness tends to be symmetric and progressive. Over time, muscles that control breathing and swallowing can weaken, which is why respiratory and nutritional care are central to managing the disease. The muscles of the heart are generally not affected, which separates SMA from some other neuromuscular conditions.

How Is Spinal Muscular Atrophy Diagnosed?

Diagnosis is made with a genetic test. A blood sample is analyzed for SMN1 deletions or mutations, and this test can confirm SMA directly. Because the genetic cause is well defined, diagnosis no longer depends on muscle biopsy as it once did.

Testing often also measures SMN2 copy number, since this helps estimate how severe the disease may be and can inform treatment decisions. Newborn screening for SMA has been added in many US states, which allows treatment to begin before symptoms appear.

Early diagnosis matters. The motor neurons lost to SMA do not grow back, so starting treatment before significant weakness develops can make a meaningful difference in outcomes.

How Is Spinal Muscular Atrophy Treated?

Several treatments for SMA have been approved, and they work in different ways. Some increase the amount of functional SMN protein the body makes. Others replace or support the SMN1 gene directly. This is a fast-moving area, and specific approvals and eligibility criteria vary by country and change over time.

What the evidence supports is this: these treatments can slow the disease and improve motor function in many people, especially when started early. They are not a cure. They do not restore motor neurons that have already been lost, and they do not reverse established weakness.

Treatment is paired with supportive care, which remains essential. This can include physical and occupational therapy, breathing support, feeding assistance, and management of scoliosis, a spinal curve that commonly develops when the muscles supporting the spine weaken. A team approach — neurologist, pulmonologist, dietitian, and therapists — is standard.

One honest point: because these treatments are relatively new, long-term data on how they perform over decades are still being gathered. What looks promising in the short term is not the same as a proven lifelong benefit, and researchers are continuing to study this.

What Is the Outlook for Someone With Spinal Muscular Atrophy?

The outlook varies widely and has changed substantially since targeted treatments became available. For the most severe infant forms, the disease was historically life-limiting, with breathing failure being the main concern. That picture has shifted for children who receive early treatment.

For milder forms, many people live into adulthood and lead full lives, though weakness and fatigue can progress over time. Breathing and spinal complications remain the main health concerns to manage.

Prognosis depends on several factors: the type of SMA, SMN2 copy number, how early treatment begins, and access to supportive care. Because treatment is new, predicting an individual’s course with confidence is difficult, and clinicians are cautious about promising specific outcomes.

Can Spinal Muscular Atrophy Be Prevented?

SMA cannot be prevented once a pregnancy has begun with two faulty SMN1 copies. The disease is genetic and present from conception.

What is possible is identifying risk before or during pregnancy. Carrier screening can tell couples whether they are both carriers. If they are, options include genetic counseling, prenatal testing, and preimplantation genetic testing during in vitro fertilization. These are personal decisions, and a genetic counselor can explain the trade-offs honestly.

Newborn screening is a separate tool. It does not prevent SMA, but it identifies affected infants early, when treatment may be most effective.